Literature DB >> 7762982

Identification of VAV2 on 9q34 and its exclusion as the tuberous sclerosis gene TSC1.

E P Henske1, M P Short, S Jozwiak, C M Bovey, S Ramlakhan, J L Haines, D J Kwiatkowski.   

Abstract

A novel widely expressed homologue of the VAV oncogene, VAV2 (53% identical residues), has been identified within the critical region for the tuberous sclerosis gene, TSC1, on human chromosome 9q34. By Southern blot analysis, analysis of allele-specific transcription, and direct sequencing of the VAV2 mRNA/cDNA from patient lymphoblastoid cell lines, we demonstrate that both alleles of this gene are expressed in TSC patients and there are no significant mutations. VAV consists of a novel array of signalling domains and is thought to play an important role in signal transduction in haematopoietic tissues where it is exclusively expressed. VAV2 is likely to serve a similar role more generally in mammalian cells, but is not the TSC1 gene.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7762982     DOI: 10.1111/j.1469-1809.1995.tb01603.x

Source DB:  PubMed          Journal:  Ann Hum Genet        ISSN: 0003-4800            Impact factor:   1.670


  24 in total

Review 1.  Regulatory and signaling properties of the Vav family.

Authors:  X R Bustelo
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

2.  Vav2 activates Rac1, Cdc42, and RhoA downstream from growth factor receptors but not beta1 integrins.

Authors:  B P Liu; K Burridge
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

3.  Small GTPase RhoG is a key regulator for neurite outgrowth in PC12 cells.

Authors:  H Katoh; H Yasui; Y Yamaguchi; J Aoki; H Fujita; K Mori; M Negishi
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

4.  Vav family proteins couple to diverse cell surface receptors.

Authors:  S L Moores; L M Selfors; J Fredericks; T Breit; K Fujikawa; F W Alt; J S Brugge; W Swat
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

5.  Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation.

Authors:  L Zeng; P Sachdev; L Yan; J L Chan; T Trenkle; M McClelland; J Welsh; L H Wang
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

6.  Small interfering RNAs as a tool to assign Rho GTPase exchange-factor function in vivo.

Authors:  Alexandra Gampel; Harry Mellor
Journal:  Biochem J       Date:  2002-09-01       Impact factor: 3.857

7.  Analysis of receptor signaling pathways by mass spectrometry: identification of vav-2 as a substrate of the epidermal and platelet-derived growth factor receptors.

Authors:  A Pandey; A V Podtelejnikov; B Blagoev; X R Bustelo; M Mann; H F Lodish
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

Review 8.  Cell growth and metastasis in pancreatic cancer: is Vav the Rho'd to activation?

Authors:  Daniel D Billadeau
Journal:  Int J Gastrointest Cancer       Date:  2002

9.  Phosphorylation-dependent and constitutive activation of Rho proteins by wild-type and oncogenic Vav-2.

Authors:  K E Schuebel; N Movilla; J L Rosa; X R Bustelo
Journal:  EMBO J       Date:  1998-11-16       Impact factor: 11.598

10.  Identification of the Eph receptor pathway as a novel target for eicosapentaenoic acid (EPA) modification of gene expression in human colon adenocarcinoma cells (HT-29).

Authors:  Joanne F Doleman; John J Eady; Ruan M Elliott; Rob J Foxall; John Seers; Ian T Johnson; Elizabeth K Lund
Journal:  Nutr Metab (Lond)       Date:  2010-07-12       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.